ONCORAL PHARMA ApS: Financial statements 2019
CVR: 35481214
Source: annual report 2019, Danish Business Authority
01/07/2018 – 30/06/2019
ONCORAL PHARMA ApS (CVR 35481214) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -1,623,620 and a net result of DKK -1,462,439. Equity in the 2019 report amounted to DKK -1,435,986.
- Gross Profit
- DKK -1,623,620
- Profit/Loss
- DKK -1,462,439
- Equity
- DKK -1,435,986
- Total Assets
- DKK 1,559,972
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -1.6 mio. | -1.5 mio. | -1.4 mio. | - |
| 2016 | - | -419 t. | -935 t. | -4.5 mio. | 0 |
| 2015 | - | -997 t. | -1 mio. | -3.6 mio. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout ONCORAL PHARMA ApS
ONCORAL PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Magnus Olafsson Corfitzen. The company is owned by Ascelia Pharma AB. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK -1,617,542 and a net result of DKK -2,313,169 compared with DKK -4,057,834 the year before. Equity in the 2025 report amounted to DKK -35,503,290.